Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RBP4 | P02753 | 6/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13121505 | 0.90 | GSK3B (0.61) | GSK3BMAPTMAPK1 | |
| SCHEMBL13289495 | 0.87 | GSK3B (0.48) | GSK3BRBP4CHEK1 | |
| SCHEMBL13289494 | 0.83 | GSK3B (0.51) | GSK3BCHEK1 | |
| SCHEMBL13121549 | 0.83 | GSK3B (0.59) | GSK3BMAPTTP53POLB | |
| SCHEMBL13288641 | 0.81 | GSK3B (0.53) | GSK3BCHEK1 | |
| SCHEMBL14545243 | 0.81 | GSK3B (0.57) | GSK3BCHEK1 | |
| SCHEMBL14418687 | 0.80 | GSK3B (0.56) | GSK3BMAPTALDH1A1CHEK1 | |
| SCHEMBL13288941 | 0.79 | KMT2A (0.55) | GSK3BTP53POLBCHEK1NAMPT | |
| SCHEMBL13121514 | 0.78 | GSK3B (0.64) | GSK3B | |
| SCHEMBL13288736 | 0.78 | GSK3B (0.53) | GSK3BCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |